Production of a Recombinant Fibrinolytic Protease from an Isolate of Serratia marcescens from the Amazon Basin

Intravenous fibrinolytic agents are essential for the treatment of cardiovascular diseases, acting through plasminogen activation to dissolve thrombi. However, current therapies are often limited by low fibrin specificity, high production costs, and side effects such as bleeding and allergic reactions. In this study, we describe a novel fibrinolytic protease, rSM519, derived from Serratia marcescens CBAM 519 and recombinantly expressed in Escherichia coli. The enzyme was purified via affinity chromatography and exhibited a molecular mass of 56 kDa. Biochemical assays revealed that rSM519 is a metalloprotease with optimal activity at pH 9.0 and 37 degrees C, significantly enhanced by Mn2+ ions. Unlike conventional agents such as tissue plasminogen activator or streptokinase, rSM519 acts directly on fibrin without requiring plasminogen activation. It efficiently degraded the alpha and beta chains of fibrinogen, mimicking plasmin-like behavior, and showed no hemolytic activity. These features position rSM519 as a promising thrombolytic candidate with potential advantages over existing therapies, including lower production costs, reduced side effects, and direct fibrin-targeting activity.